- Home
- HG vs BEAM Comparison
HG vs BEAM Comparison
Compare HG & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HG | BEAM |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HG | BEAM |
|---|---|---|
| Price | $28.28 | $26.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $29.00 | ★ $48.09 |
| AVG Volume (30 Days) | 454.7K | ★ 2.0M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.19 | N/A |
| Revenue | ★ $2,745,461,000.00 | $55,701,000.00 |
| Revenue This Year | $25.41 | N/A |
| Revenue Next Year | $0.82 | $26.52 |
| P/E Ratio | $6.72 | ★ N/A |
| Revenue Growth | ★ 21.12 | N/A |
| 52 Week Low | $16.80 | $13.53 |
| 52 Week High | $28.16 | $35.25 |
Technical Indicators
Market Signals| Indicator | HG | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 69.59 | 56.13 |
| Support Level | $25.93 | $25.86 |
| Resistance Level | $27.88 | $28.28 |
| Average True Range (ATR) | 0.52 | 1.63 |
| MACD | 0.07 | 0.25 |
| Stochastic Oscillator | 84.44 | 58.35 |
Price Performance
Historical ComparisonAbout HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.